FDA Approves Roivant's LISRAYA (brepocitinib) as First Targeted Therapy for Dermatomyositis

The FDA has approved LISRAYA (brepocitinib) 30 mg, Roivant Sciences’ (Nasdaq: ROIV) once-daily oral pill, for adults with dermatomyositis. The decision, announced August 27 at 3:29 PM ET through Roivant’s Priovant Therapeutics subsidiary, makes LISRAYA the first and only targeted therapy cleared for the disease and lands roughly five weeks ahead of the September 30 PDUFA target action date. The drug is available in the U.S. immediately.

Dermatomyositis is a rare systemic autoimmune disease that causes progressive muscle weakness alongside painful, itchy, disfiguring skin lesions. It affects roughly 50,000 adults in the U.S., and for decades the standard of care has relied on chronic high-dose steroids, non-specific immunomodulators, and IVIG. None of those target the underlying disease biology. Brepocitinib is a first-in-class dual TYK2/JAK1 inhibitor designed to block the inflammatory cytokines implicated in the disease.

The approval rests on the Phase 3 VALOR trial, the largest dermatomyositis study ever conducted. On a combined measure of disease improvement and steroid sparing, 55% of patients on LISRAYA achieved at least moderate improvement on the myositis Total Improvement Score with minimal or no steroid use by the end of the 52-week study, versus 30% on placebo. Among patients taking 7.5 mg/day or more of oral corticosteroids at baseline, 62% tapered to 2.5 mg/day or less (versus 38% on placebo), and 45% stopped steroids entirely (versus 29%). Patients on LISRAYA also reported more than four times the improvement in overall disease activity compared with placebo. Primary results were published in the New England Journal of Medicine in March 2026, with skin-specific secondary endpoints in JAMA Dermatology in August 2026.

The label carries the JAK-class boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. The most common adverse reactions in VALOR were upper respiratory tract infection, headache, fatigue, urinary tract infection, nausea, and bronchitis. LISRAYA is not recommended in combination with other JAK or TYK2 inhibitors or biologic DMARDs.

The early approval does more than clear a single indication. It de-risks the wider brepocitinib franchise, which is in late-stage development for non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris, and it validates Roivant’s “Vant” model of building subsidiaries around individual assets. We broke down the pre-approval setup, including the $25 billion valuation question, in our earlier analysis.

Shares of ROIV closed up 2.3% at $37.58 on August 27, with the announcement arriving late in the session. Roivant hosts an investor call to discuss the launch tomorrow, August 28, at 8:00 AM ET. The full prescribing information is available at lisrayahcp.com/pi.

What to watch next: the August 28 investor call for launch details, pricing, and commercial guidance, plus any read-through to the uveitis and sarcoidosis programs.

What It Means for the Trade

A 2.3% move on a first-in-disease approval tells you the market had largely priced this in — and it frames the honest bull/bear argument. The bull case is that LISRAYA is the first and only targeted therapy for a 50,000-patient U.S. disease that has been treated with steroids and non-specific immunosuppression for decades, with label language on steroid tapering that directly targets the biggest complaint in dermatomyositis care. First-in-class in an underserved autoimmune niche has historically supported strong pricing and rapid specialist adoption. The bear case is the Roivant conglomerate structure and the $25 billion valuation question: the approval de-risks a real product, but at $37.58 the stock still has to grow into a multi-franchise story. The myositis backdrop shifted the same month: argenx’s ALKIVIA Phase 3 hit the overall endpoint but missed significance in the DM subtype - the ARGX myositis analysis explains why that miss leaves DM to LISRAYA by default.

Five weeks of early approval is worth real money in a launch year — that is five extra weeks of Tabular-compiled prescriptions in front of any payer negotiations.

Franchise Context

The JAK-class boxed warning is the commercial headwind to watch. Prescribers in rheumatology and dermatology have been trained to reserve JAK inhibitors after biologics fail, and label language recommending against combinations with other JAK/TYK2 inhibitors or biologic DMARDs narrows the positioning. What fights back is the steroid-sparing data: 62% of patients on 7.5 mg/day or more of prednisone tapering to 2.5 mg or less, and 45% stopping steroids entirely versus 29% on placebo. Chronic steroid toxicity is what actually destroys quality of life in this disease, and that dataset gives sales reps a concrete story.

The bigger prize is pipeline read-through. Late-stage brepocitinib programs in non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris now carry a validated regulatory and commercial package. Approval of a first targeted DM therapy meaningfully raises the probability the market assigns to those follow-on indications.

Risks and What Could Go Wrong

1. Launch ramp disappoints. Dermatomyositis is small, specialist-dense, and slow to adopt. Orphan-style pricing only holds if volume arrives.
2. JAK safety anxiety limits prescribing to refractory patients, capping the addressable population well below the headline 50,000.
3. Roivant’s sum-of-the-parts discount persists even with a commercial product, as it has across the Vant portfolio.